Pascal Soriot, AstraZeneca CEO (Photo by Chris Jackson/Getty Images)
May 17, 2022 07:27 AM EDT
Deals
Coronavirus

As­traZeneca picks up suite of new Covid-19 an­ti­bod­ies, shin­ing spot­light on Ox­ford-tied start­up

Amber Tong

As­traZeneca is tak­ing an­oth­er stab at de­vel­op­ing an­ti­bod­ies for Covid-19.

Hav­ing part­nered with Van­der­bilt Uni­ver­si­ty re­searchers to de­vel­op the long-act­ing an­ti­body com­bo now known as …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

The Biden ad­min­is­tra­tion wants Medicare and Med­ic­aid to cov­er GLP-1s. Will the Trump White House al­low it?

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Ax­some moves to­ward NDA fil­ing for nar­colep­sy drug fol­low­ing pos­i­tive Phase 3 da­ta

Soleno’s rare pe­di­atric dis­ease drug faces PDU­FA de­lay by three months

A service from the Financial Times